Patent · US Active

Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein

US10093665B2 · kind B2 · utility

0Cited by

0References

27Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Jeewan Thakur · Basel, CH
Dong Yang · Seojong-myeon, KR
Lili Feng · Pine Brook, US

Key dates

Filing date	Nov 30, 2016
Grant date	Oct 9, 2018
Priority date	—
Expiry date	Nov 30, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to crystalline form of (S)—N—((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (S)—N—((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.